A Self-Crossover Controlled Clinical Study of Ispro Mix 50/50 and Aspart Mix 30/70 in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

OBJECTIVE To evaluate the efficacy of lispro Mix 50/50 and aspart Mix 30/70 in patients with newly diagnosed type 2 diabetes mellitus. METHODS Outpatients and inpatients(n=56) with newly diagnosed type 2 diabetes mellitus were treated with ispro mix 50/50 or aspart mix 30/70 respectively, in a randomly self-crossover controlled clinical test. After treatment, the following indicators were observed and compared: fasting plasma glucose(FPG), postprandial plasma glucose (2h-PG), glycosylated hemoglobin (HbA1c), the total amount of insulin, body mass index(BMI) and the incidence of hypoglycemia. RESULTS The levels of fasting plasma glucose was not different between two groups. However, the control of postprandial plasma glucose and HbA1c was significantly more effective in Lispro Mix 50/50 group than in other groups(P<0.05). Furthermore, the total amount of insulin was lower in Lispro Mix 50/50 group (P<0.05). The incidence of hypoglycemia was not statistically different between the two groups (P>0.05). But the hypoglycemia of ispro mix 50/50 happened more in the daytime, and the hypoglycemia of aspart Mix 30/70 happened more in the night. CONCLUSIONS Lispro mix 50/50 and aspart Mix 30/70 are both effective in treatment of type 2 diabetes. But Lispro mix 50/50 is more effective in the control of postprandial plasma glucose and the total amount of insulin and makes less nighttime hypoglycemic episodes.